Evolving Treatment Options in Plaque Psoriasis: Implications of Emerging TYK2 Inhibitors for Managed Care

A satellite symposium held at PBMI 2026.

To attend PBMI in person, register here

Program Information

Plaque psoriasis is a chronic, systemic immune-mediated inflammatory condition that results in profound clinical, psychosocial, and economic burden for affected patients. While management traditionally centers on topical therapies, many patients experience treatment failure or require escalation due to disease severity, significant body surface area involvement, or the presence of systemic comorbidities, such as psoriatic arthritis. This session focuses on gaps in the transition from topical to systemic therapy, specifically focusing on the evolving role of oral tyrosine kinase 2 (TYK2) inhibitors in plaque psoriasis. These selective small molecules modulate core inflammatory pathways, with a differentiated safety and efficacy profile compared with Janus kinase inhibitors as well as different administration considerations compared with injectable biologics. Speakers will review safety and efficacy data for approved and emerging TYK2 inhibitors while sharing insights into how these oral options address treatment sequencing gaps in patient-centered care. Additionally, the faculty will utilize real-world patient scenarios to illustrate evidence-based escalation strategies while navigating complex managed care decision points such as prior authorization and step therapy requirements to optimize formulary strategies and support timely access to treatment for patients with moderate to severe plaque psoriasis.

Target Audience: Managed Care Pharmacists
Type of activity: Application
Release date: September 10, 2026
Expiration date: November 10, 2026
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Describe the disease burden, clinical presentation, and underlying pathophysiology of plaque psoriasis, including the role of tyrosine kinase 2 (TYK2) in the inflammatory cascade
• Compare emerging TYK2 inhibitors with other systemic therapies for plaque psoriasis based on mechanisms of action and available clinical data
• Apply evidence-based criteria to inform appropriate transition from topical to systemic therapy
• Identify managed care strategies that support appropriate access to new and emerging therapies for patients with moderate to severe plaque psoriasis

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-227-L01-P. The activity is available for CE credit through November 10, 2026

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Disclosures

Aderonke Adeboye, PharmD, BCPS; and Casey Koch, PharmD, MBA, have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Adam Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated. 

At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose. 

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms